Nonsedating antihistamines in the treatment of severe chronic idiopathic urticaria: Are they used optimally? [9]

British Journal of Dermatology

Volumn 154, Issue 5, 2006, Pages 1012-1013

  Cheung, S T ^a   Tucker, W ^a  

^a WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CYCLOSPORIN; DESLORATADINE; DESLORATIDINE; FEXOFENADINE; HYDROXYZINE; MIZOLASTINE; TERFENADINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; CARDIOTOXICITY; CASE REPORT; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; SEDATION; UNITED KINGDOM; UNITED STATES; URTICARIA;

CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MIDDLE AGED; URTICARIA;

EID: 33645824359     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07207.x     Document Type: Letter

References (15)

1. Kozel MM Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004 64 2515 36.
2. Chua SL Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005 153 216 17.
3. Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol 2005 30 582 3.
4. Grattan C Powell S Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 2001 144 708 14.
5. Sale ME Barbey JT Woosley RL et al. The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther 1994 56 295 301.
6. Pratt CM Mason J Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999 83 1451 4.
7. Murdoch D Goa KL Keam SJ. Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 2003 63 2051 77.
8. Craig-McFeely PM Acharya NV Shakir SA. Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol 2001 57 313 20.
9. Pinto YM van Gelder IC Heeringa M Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999 353 980.
10. Zuberbier T Henz BM. Use of cetirizine in dermatologic disorders. Ann Allergy Asthma Immunol 1999 83 476 80.
11. Hampel F Ratner P Mansfield L et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003 91 354 61.
12. Walsh GM Annunziato L Frossard N et al. New insights into the second generation antihistamines. Drugs 2001 61 207 36.
13. Champion RH Roberts SO Carpenter RG Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969 81 588 97.
14. Quaranta JH Rohr AS Rachelefsky GS et al. The natural history and response to therapy of chronic urticaria and angioedema. Ann Allergy 1989 62 421 4.
15. van der Valk PG Moret G Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002 146 110 13.